Abecma
Bristol Myers Squibb to Acquire 2seventy Bio for $286M
2seventy sold most of its pipeline candidates except for CAR T-cell therapy Abecma to Regeneron last year.
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies.
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
BMS, 2seventy End Phase III Trial of Maintenance Abecma in Multiple Myeloma Due to Low Enrollment
The firms said the trial had enrolled only 10 percent of the target study population after one year.
Jul 26, 2024
Apr 25, 2024